Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
CME Group director Daniel G. Kaye reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Kaye now beneficially owns 4,200 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Type: Stock Grant (Code A)
- Reporting Person Role: Director
- Ownership Form: Direct
- Filing was submitted by Jenelle Chalmers on behalf of Daniel G. Kaye
CME Group director Charles P. Carey reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 Class A Common Stock shares at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Carey's beneficial ownership consists of:
- 5,779 shares held indirectly through trust
- 185 shares held indirectly through firm
- 0.375 shares held indirectly through partnership
The Form 4 filing indicates this was a planned acquisition under the director compensation program rather than an open market transaction. No derivative securities were involved in this transaction.
CME Group director William W. Hobert reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 879 shares of Class A Common Stock at a price of $273.03 per share through the CME Group Director Stock Plan.
Following the transaction, Hobert's holdings include:
- 86,598 shares held directly
- 40,000 shares held indirectly through his firm
The transaction was executed pursuant to the company's Director Stock Plan, as amended and restated. The Form 4 was filed on behalf of Hobert by Jenelle Chalmers on June 26, 2025, within the required reporting timeframe.
CME Group director Martin J. Gepsman reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Gepsman now beneficially owns a total of 25,299 shares directly. The filing indicates this was a standard director compensation grant rather than an open market purchase.
- Transaction Type: Stock Award (Code A)
- Ownership Form: Direct
- Filing Status: Individual filing
- Role: Director (non-employee)
This insider transaction represents routine director compensation and aligns with standard corporate governance practices for board member equity compensation.
CME Group Inc. (CME) filed a Form 4 disclosing that Director Howard J. Siegel acquired 879 shares of Class A common stock on 06/25/2025 at $273.03 per share under the company’s Director Stock Plan. Following the purchase, Siegel holds 47,791 shares directly and 21,873 shares indirectly through a trust. No derivative transactions or share dispositions were reported.
Form 4 filing – CME Group Inc. (CME)
Director Dennis Suskind received 532 Class A common shares on 25 Jun 2025 under the CME Group Director Stock Plan. The grant price recorded for reporting purposes is $273.03 per share, implying a total market value of roughly $145 k. Following the award, Suskind’s direct beneficial ownership rose to 3,447 shares, an increase of about 18%. No open-market purchases, sales, or derivative transactions were reported, and there is no indication of a 10b5-1 trading plan. The transaction represents routine director compensation and does not materially affect CME’s share count or capital structure.
Form 4 overview: On 06/25/2025 CME Group Inc. (CME) director Kathryn Benesh reported an acquisition of Class A common stock.
The filing shows a single non-derivative transaction coded “A(1),” indicating a grant under the company’s amended and restated Director Stock Plan. Benesh received 532 shares at a reference value of $273.03 per share. Following the grant, her aggregate beneficial ownership increased to 2,106.948 shares, held directly.
No derivative securities were listed and the Form 4 contains no sales, option exercises, or 10b5-1 plan activity. The grant is routine annual director compensation rather than an open-market purchase, so cash outlay by the director is not implied. While the transaction modestly aligns director and shareholder interests, it represents an immaterial fraction of CME’s ~360 million Class A shares outstanding and therefore is unlikely to affect valuation or trading dynamics.
Insider transaction overview: On 06/25/2025 director Robert J. Tierney Jr. filed a Form 4 reporting the acquisition of 532 shares of CME Group Inc. (CME) Class A common stock.
Key details
- Transaction type: Code A – acquisition under the CME Group Director Stock Plan.
- Per-share price reported: $273.03.
- Total shares acquired: 532.
- Beneficial ownership after the transaction: 13,700 direct shares.
The filing indicates the shares were granted pursuant to the company’s director compensation plan rather than an open-market purchase. No derivative securities were reported. The director remains classified as an “Officer/Director” insider and the filing was signed on 06/26/2025 by attorney-in-fact Jenelle Chalmers.
While the size of the acquisition is modest relative to CME’s average daily volume, any increase in board-level ownership can be viewed as enhancing alignment between the director and shareholders.
CME Group Inc. (CME) – Form 4 insider activity dated 06/25/2025
Director William R. Shepard reported three separate Class A common-stock acquisitions:
- 879 shares were granted under the CME Group Director Stock Plan (transaction code A) with a reference price of $273.03. Shares are held indirectly in a trust. Post-grant indirect holdings: 257,939.99 shares.
- Through a dividend-reinvestment plan, the trust purchased 256.097 shares in the open market (code P) at an average price of $270.53. Indirect holdings after the trade: 258,196.087 shares.
- Shepard’s direct account purchased 11.29 shares at $270.53, raising direct ownership to 2,454.76 shares.
No derivative securities were reported. The filing was signed on 06/26/2025.